Opus GeneticsIRD +7.38%24 PS Ratio is 24.69 as of Jun. 27, 2026, which is 637% above its 10-year median of 3.35. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Opus Genetics ranks worse than 68.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Opus Genetics's share price is $4.00.
Opus Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.16. Hence, Opus Genetics's PS Ratio for today is 24.69.
The historical rank and industry rank for Opus Genetics's PS Ratio or its related term are showing as below:
IRD'
s PS Ratio Range Over the Past 10 Years
Min: 1.06 Med: 3.35 Max: 761.43
Current: 24.69
During the past 7 years, Opus Genetics's highest PS Ratio was 761.43. The lowest was 1.06. And the median was 3.35.
IRD's PS Ratio is ranked worse than 68.38% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs IRD: 24.69
Opus Genetics Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Opus Genetics was -64.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -51.00% per year.
During the past 7 years, Opus Genetics's highest 3-Year average Revenue per Share Growth Rate was 117.40% per year. The lowest was -51.00% per year. And the median was 33.20% per year.
Back to Basics: PS Ratio
Opus Genetics (NAS:IRD) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Opus Genetics PS Ratio Related Terms
Opus Genetics PS Ratio Historical Data
* Premium members only.
The historical data trend for Opus Genetics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Opus Genetics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Opus Genetics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Opus Genetics's Share Price of today is $4.00. Opus Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Opus Genetics (IRD) has a PS Ratio of 24.69 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Opus Genetics and its competitors. This is 637% above median its historical median of 3.35. Over the past decade, Opus Genetics' PS Ratio has ranged from 1.06 to 761.43. According to the industry distribution chart, Opus Genetics ranks #640 out of 936 companies in the Biotechnology industry, placing it in the top 68.4%.
Is Opus Genetics' PS Ratio too high?
Opus Genetics' current PS Ratio of 24.69 is 637% above median its 10-year median of 3.35. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 761.43. The Biotechnology industry median PS Ratio is 9.17. Opus Genetics' value of 24.69 is 169.4% above this industry median. Based on the distribution chart, Opus Genetics ranks #640 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' PS Ratio compare to IFRX and RGNX?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #640 out of 936 companies for PS Ratio. This places Opus Genetics in the lower half of its industry. The industry median PS Ratio is 9.17. Opus Genetics' value of 24.69 is 169.4% above this benchmark. Historically, Opus Genetics' own PS Ratio has ranged from 1.06 to 761.43 over the past decade. While the company's 10-year median is 3.35 vs. the industry median of 9.17, Opus Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Opus Genetics's current PS Ratio of 24.69 is 169.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Opus Genetics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Opus Genetics's current PS Ratio is 24.69, which is 637% above median its own 10-year median of 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.00 — trading 981.1% above its estimated fair value. The current PS Ratio is 24.69, which is 637% above median its 10-year median of 3.35 and 169.4% above the Biotechnology industry median of 9.17. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Opus Genetics (IRD), the current PS Ratio is 24.69 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $4.00 is trading 981.1% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
PS Ratio: 24.69 (637% above median its 10-year median of 3.35)
GF Value™: $0.37 vs. price of $4.00 (981.1% above fair value)
Industry Position: 169.4% above the Biotechnology median (#640 of 936)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
